Verification evidence is still being completed.
PDF / print export
GLX Analytix ApS
Copenhagen, Denmark
- Verified lead
- Brian Dellavalle
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer and Founder
- 2026 technical specialization
- Glycomics Biomarker Diagnostics, Neurodegenerative and Autoimmune Disease Monitoring
- Review cycle
- 24 April 2026
- Full address
- COBIS, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- GLX Analytix people section naming Brian Dellavalle as CEO and Founder.
- Editorial note
- Copenhagen glycomics diagnostics startup with named founder CEO, a GlycA and GlycB-class biomarker platform, and a public commercialization-readiness signal via 360Dx.
Glycomics Biomarker Diagnostics, Neurodegenerative and Autoimmune Disease Monitoring
Public founder CEO disclosure, 360Dx commercialization coverage, COBIS tenant record
Copenhagen glycomics diagnostics startup with named founder CEO, a GlycA and GlycB-class biomarker platform, and a public commercialization-readiness signal via 360Dx.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Copenhagen, Denmark
GLX Analytix ApS
Glycomics Biomarker Diagnostics, Neurodegenerative and Autoimmune Disease Monitoring · Diagnostics platform development
Copenhagen glycomics diagnostics startup with named founder CEO, a GlycA and GlycB-class biomarker platform, and a public commercialization-readiness signal via 360Dx.
- Lead
- Brian Dellavalle (verified ↗)
- Address
- COBIS, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Diagnostics platform development
- Capabilities
- Glycomics Biomarker Platform · AI-Augmented Biomarker Analytics · Neurodegenerative and Autoimmune Targets
- Founded
- 2017
- Headcount
- 1-10
Clinical profileSTATUS: VERIFIED APRIL 2026
Brian Dellavalle
Chief Executive Officer and Founder
Full addressCOBIS, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Diagnostics platform development
Copenhagen, Denmark. Glycomics Biomarker Diagnostics, Neurodegenerative and Autoimmune Disease Monitoring. Review completed on 24 Apr 2026.
Danish Medicines Agency and EU IVDR for future launches
Public founder CEO disclosure, 360Dx commercialization coverage, COBIS tenant record
Glycomics Biomarker Diagnostics, Neurodegenerative and Autoimmune Disease Monitoring
Copenhagen glycomics diagnostics startup with named founder CEO, a GlycA and GlycB-class biomarker platform, and a public commercialization-readiness signal via 360Dx.
Editorial note
GLX Analytix is a Copenhagen diagnostics startup with a named founder CEO, a proprietary glycomics biomarker platform, and a public commercialization-readiness signal in 360Dx coverage.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Glycomics Biomarker Platform
AI-Augmented Biomarker Analytics
Neurodegenerative and Autoimmune Targets
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Glycomics biomarker assay
AI analytics pipeline
Clinical-validation collaborations
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is GLX Analytix ApS located?
- GLX Analytix ApS operates from COBIS, Ole Maaloes Vej 3, 2200 Copenhagen, Denmark, Copenhagen, Denmark.
- Who runs GLX Analytix ApS?
- GLX Analytix ApS is led by Brian Dellavalle, Chief Executive Officer and Founder. Verified 24 Apr 2026.
- What does GLX Analytix ApS do?
- Copenhagen glycomics diagnostics startup with named founder CEO, a GlycA and GlycB-class biomarker platform, and a public commercialization-readiness signal via 360Dx. Core capabilities: Glycomics Biomarker Platform, AI-Augmented Biomarker Analytics, Neurodegenerative and Autoimmune Targets.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.